Pharmacokinetics of Murine Tumor Necrosis Factor
- 1 January 1986
- journal article
- research article
- Published by Informa UK Limited in Immunopharmacology and Immunotoxicology
- Vol. 8 (1), 89-97
- https://doi.org/10.3109/08923978609031087
Abstract
The in vivo administration of tumor necrosis factor (TNF) provides a new approach to the immunotherapeutic treatment of tumors. We evaluated the pharmacokinetics of murine tumor necrosis factor in mice as a model for application in the human system. TNF had a clearance of 0.013 ml/min/g and a serum half life of 10.5 minutes. Its volume of distribution was consistant with the extracellular space. This information can provide parameters by which to select optimal modes of treatment for eradication of in vivo neoplasms.Keywords
This publication has 6 references indexed in Scilit:
- Molecular Cloning of the Complementary DNA for Human Tumor Necrosis FactorScience, 1985
- Cloning and expression in Escherichia coli of the gene for human tumour necrosis factorNature, 1985
- Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxinNature, 1984
- Comparison of in vitro cell cytotoxic assays for tumor necrosis factorJournal of Immunological Methods, 1984
- Corynebacterium parvum as the Priming Agent in the Production of Tumor Necrosis Factor in the Mouse2JNCI Journal of the National Cancer Institute, 1977
- An endotoxin-induced serum factor that causes necrosis of tumors.Proceedings of the National Academy of Sciences of the United States of America, 1975